CD274 and neoplasm: First‐line pembrolizumab or atezolizumab monotherapy is an effective regimen in patients with NSCLC with high PD‐L1 expression in tumor cells; however, it is unclear whether ICI monotherapy or combination immunotherapy is beneficial.10, 22